Yurogen Biosystems
- Company typePrivate
- Founded2014
- HeadquartersWorcester, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
Yurogen Biosystems firmographics
Firmographics- Name
- Yurogen Biosystems
- Legal name
- Yurogen Biosystems
- Website
- https://yurogen.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Yurogen Biosystems industry classification
Industry- Product category
- Contract Research Organization (CRO) Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Preclinical CROs (Discovery/Pharmacology/DMPK) (HLAGAAAB)
- akta.pro secondary industry
- Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity) (HLAGAAAD)
Keywords
Where Yurogen Biosystems is headquartered
LocationHeadquarters
- HQ city
- Worcester
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Yurogen Biosystems business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Custom Antibody Development Services: CRO services for monoclonal antibody development including rabbit monoclonal, camelid single domain, and human monoclonal antibodies. Services include functional clone identification, high throughput screening, and antibody engineering. Revenue generated through project-based contracts with flexible customization and step-wise billing. No milestone or royalty fees charged.
- Bioanalytical Services: PK (pharmacokinetics) and ADA (anti-drug antibody) assay reagent development with fast turnaround time to accelerate clinic studies. Targets multiple drug formats.
- Recombinant Protein Expression: Custom recombinant protein expression services including extracellular, membrane, and intracellular proteins, small molecule compounds, and PTM-specific proteins.
- SPR Service: Surface Plasmon Resonance (SPR) analytical services for binding affinity measurement and characterization.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Custom project-based pricing with flexible service tiers |
Go-to-market motion2 records
Distribution channels2 records
Marketing channels5 records
Yurogen Biosystems product offering
Product offeringCore offering
Yurogen Biosystems is a contract research organization (CRO) that provides custom monoclonal antibody discovery, engineering, and production services using its proprietary SMab™ single B-cell technology platform. The company develops rabbit, llama (camelid), and human monoclonal antibodies for pharmaceutical, biotechnology, diagnostics, and academic research customers, alongside complementary bioanalytical, recombinant protein expression, and SPR-based binding analysis services.
Product overview
Yurogen Biosystems offers an integrated portfolio of antibody discovery, engineering, and production services built around its proprietary SMab™ single-B-cell technology platform. The platform serves as the foundation for developing monoclonal antibodies from multiple species (rabbit, camelid, human) and supports applications across scientific research, in vitro diagnostics, and drug discovery. Service offerings include Rabbit Monoclonal Antibody Development, Camelids Single Domain Antibody Development, scFvs for in vivo CAR-T, PK/ADA Assay Reagent Development, Bioanalytical Services, Antibody Engineering, Recombinant Expression, and SPR Service. The company operates from Boston, Massachusetts (established 2014) with a Chinese branch in Wuhan (2018), and merged with ABclonal Science Inc in 2021.
Differentiator
Problem solved
Functional benefit
Brands
- SMab™: Proprietary single-B-cell-based monoclonal antibody development technology platform used for developing rabbit, llama, and human monoclonal antibodies
Products and services
- Rabbit Monoclonal Antibody Development Service
- Camelid Single Domain Antibody Development
- scFvs for In Vivo CAR-T
- PK and ADA Assay Reagent Development
- Bioanalytical Services
- Antibody Engineering
- Recombinant Expression
- SPR Service
Quantifiable outcome
- 2000+ projects successfully delivered
- +2 more outcomes
Companies that use Yurogen Biosystems
Customer profileNamed customers17 records
Segments4 records
Ideal customer profiles3 records
Yurogen Biosystems technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Yurogen Biosystems partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- GV Research Platform (GVRP)coreStrategic distribution partnership announced in February 2026 to expand access to Yurogen's advanced antibody discovery capabilities in India. Under the agreement, GVRP serves as the commercial interface handling market access and client engagement in India for biotechnology and pharmaceutical companies as well as academic research institutions. Yurogen retains responsibility for all scientific execution and service delivery using its proprietary SMab™ single B-cell technology platform. The partnership aims to support India's growing life sciences ecosystem by providing access to globally benchmarked antibody discovery services for early-stage drug discovery and translational research.
Scale indicators4 records
Recent moves7 records
Expansion highlights5 records
Yurogen Biosystems competitors and assessment
Company assessmentBroad incumbents
- WuXi Biologics: Global biologics CRO/CDMO with significant antibody discovery, cell-line development, and manufacturing capabilities. A much larger incumbent that competes for therapeutic antibody programs alongside Yurogen, especially with biotech customers seeking integrated discovery-to-manufacturing partners.
- BioLegend (Revvity): Major antibody reagent and custom services provider now part of Revvity. Comparable to Yurogen in serving academic and pharma customers with research and diagnostic antibody needs, but with a much larger catalog and global scale.
- Cell Signaling Technology: Established antibody reagents and services company with strong academic and biotech customer overlap with Yurogen, particularly in research-grade and validation-grade antibodies. A broader incumbent rather than a pure custom-discovery competitor.
- Charles River Laboratories: Large, diversified CRO with end-to-end discovery-through-manufacturing capabilities, including a robust antibody discovery and biologics testing business. Overlaps with Yurogen as a competitor for antibody discovery projects but offers much broader scale and services.
Direct peers
- GenScript: Major life-sciences services and products provider with a dedicated antibody services business covering custom mAb development, protein expression, and bioanalytical assays. Directly overlaps with Yurogen's rabbit, camelid, and human mAb discovery, protein expression, and SPR offerings.
- Creative Biolabs: Custom antibody services CRO offering rabbit mAb, human mAb, camelid/nanobody, scFv, and CAR-T-related antibody development. Highly comparable scope and customer base (pharma, biotech, academic) to Yurogen's service menu.
- Sino Biological: China-headquartered provider of recombinant proteins, antibodies, and related CRO services with a global customer base. Comparable to Yurogen in combining antibody discovery, recombinant expression, and a strong Asia-Pacific presence through its Sino-based operations.
- AbCellera Biologics: Public antibody discovery CRO/platform company that pioneered single B-cell screening at scale, making it the most direct technical competitor to Yurogen's SMab™ platform. Both serve biotech and pharma with custom antibody discovery, though AbCellera operates at much larger scale with platform-partnership economics.
- LakePharma (Curia): Custom antibody discovery, engineering, and bioanalytical CRO serving pharma and biotech customers. Directly comparable service portfolio (custom mAb development, protein expression, SPR/analytical) to Yurogen, with overlapping customer segments.
- ImmunoPrecise Antibodies: CRO focused on custom antibody discovery and characterization across multiple species (rabbit, llama, human), closely overlapping Yurogen's service portfolio. Both target therapeutic and diagnostic mAb programs for pharma, biotech, and academic clients.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Yurogen Biosystems social profiles
Digital presenceYurogen Biosystems compliance and trust
Trust signalCompliance1 record
Yurogen Biosystems financial estimates
Financial estimateRevenue estimate
Valuation estimate
Yurogen Biosystems leadership team
Management profileNumber of profiles
Yurogen Biosystems funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Yurogen Biosystems M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Yurogen Biosystems
What does Yurogen Biosystems do?
Yurogen Biosystems is a contract research organization (CRO) that provides custom monoclonal antibody discovery, engineering, and production services using its proprietary SMab™ single B-cell technology platform. The company develops rabbit, llama (camelid), and human monoclonal antibodies for pharmaceutical, biotechnology, diagnostics, and academic research customers, alongside complementary bioanalytical, recombinant protein expression, and SPR-based binding analysis services.
Is Yurogen Biosystems a public or private company?
Yurogen Biosystems is a private company. It is classified as corporate owned and is currently operating.
When was Yurogen Biosystems founded?
Yurogen Biosystems was founded in 2014. It employs 1 to 10 people.
Where is Yurogen Biosystems based?
Yurogen Biosystems is headquartered in Worcester, United States, in the North America region.
How does Yurogen Biosystems make money?
Four revenue lines are on record. Custom Antibody Development Services are the primary driver. The others are bioanalytical Services, recombinant Protein Expression and SPR Service.
Who are Yurogen Biosystems's main competitors?
Broad incumbents on record are WuXi Biologics, BioLegend (Revvity), Cell Signaling Technology and Charles River Laboratories. Direct peers are GenScript, Creative Biolabs, Sino Biological, AbCellera Biologics, LakePharma (Curia) and ImmunoPrecise Antibodies.
Does Yurogen Biosystems have an API?
No public API is recorded for Yurogen Biosystems.
What industry is Yurogen Biosystems in?
Yurogen Biosystems's product category is Contract Research Organization (CRO) Services. Its primary akta.pro industry code is HLAGAAAB, Preclinical CROs (Discovery/Pharmacology/DMPK), with a secondary code of HLAGAAAD, Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity). Its NAICS code is 541714 and its SIC code is 8731.